HOME >> BIOLOGY >> NEWS
Discovering what genes do the high-throughput way

by the screen to characterize the effects of the RNAi treatment on the cells. They created a formal set of criteria to judge the cells consisting of seven classes of change that could have been induced. These included changes to cell number, shape, size and viability. Any changes were only considered significant if both scientists recorded them in replica experiments.

The researchers were also keen to find out if their method could be used to screen for genes that worked in, or inhibited specific molecular pathways. Screens in whole flies for genes that modify the effect of a particular genetic mutation have proved powerful, though time consuming. By adding two sets of double stranded RNA to each well, one that targeted the tumor suppressor gene pten and the other the gene to be tested, the researchers found that they were able to identify genes that modified the effects of inhibiting pten in cells. "These results demonstrate that modifier screens, as previously done in vivo, can be extended to RNAi screening methodology in cell culture", write the researchers.

Drug companies are becoming interested in this technique, as the rate-limiting step in cell-based drug discovery is finding out which protein is inhibited by a particular drug. Using Perrimon's method they can screen to see which gene, when inhibited, changes the cell in the same way as adding the drug.

"RNAi screens can complement classical Drosophila genetics to assign functions to both known and novel genes," write the researchers. "The same technology can be easily adapted to a wide variety of cell-based studies and a greater genomic scale."

Baum says, "The major difference between this and whole fly screens is that here we can be systematic. We can choose to look at any cell biological process and systematically test the set of genes that could be involved. In the future we will be able to screen the full genome in a few weeks, and look at any cell biological phenomenon.
'"/>

Contact: Gemma Bradley
press@biomedcentral.com
44-207-323-0323
BioMed Central
30-Sep-2003


Page: 1 2 3

Related biology news :

1. Discovering new regulators of the immune system
2. Discovering the Tree of Life
3. Discovering Virology From Beijerinck To Hyperlinks
4. "Discovering Biological Diversity" Is AAAS Topic For USGS Manager
5. Belgian researchers explore revolutionary approach to angiogenesis
6. Tracing genes, biologists show lizard migration is traced to Florida
7. Certain genes boost fish oils protection against breast cancer
8. Fossil genes reveal how life sheds form and function
9. Missing genes may help explain why plague bacteria are so deadly
10. Do genes respond to global warming?
11. Genetic map of important tree genes outlined

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Discovering what genes the high throughput way

(Date:10/15/2014)... of Life, is a non-traditional biophysics textbook and it ... is a journey of discovery into biological systems and ... biological regulation. It is about how our genes make ... the billions of cells in an organism. It quantifies ... principles, which can be found on both large and ...
(Date:10/15/2014)... Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market releases photos and video ... Square on Monday October 13 th . ... Tunnel and angel investor Mr. Chad A. Verdi ... of NXT-ID thanked his investors and employees "for their work and ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to ... the development of skin cancers by turning on an ... skin cells. , Previously considered protective, SIRT6 is part ... help regulate genomic stability and prevent some of the ... damage, which can lead to cancer. This study, in ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 22, 2014 Physicians Choice Laboratory ... pharmacogenetics menu, which enables healthcare providers to individualize ... PCLS’s evidence-based results, healthcare providers are better able ... therapy, while minimizing risks for adverse drug reactions ... to the FDA [1] more than 2.2 million ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
(Date:10/20/2014)... N.J. (PRWEB) October 20, 2014 ... the Sidney Kimmel Cancer Center at Thomas Jefferson ... , Through the Strategic Alliance Partnership program, ... OncLive will collaborate to raise awareness of the ... treatment, and other projects. Clinicians and other health ...
Breaking Biology Technology:PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3
Cached News: